Peter Arduini - Bristol Myers Independent Director
| BMY Stock | USD 53.07 2.12 3.84% |
Director
Mr. Peter J. Arduini serves as Independent Director of the Company effective April 1, 2016. Mr. Arduini was President and Chief Executive Officer at Integra LifeSciences Holdings Corporationrationration, a global medical technology company since January 2012 and currently serves as a member of Integra Board of Directors. He served as President and Chief Operating Officer of Integra from November 2010 to January 2012. Before joining Integra, Mr. Arduini was Corporationrationrate Vice President and President of Medication Delivery, Baxter Healthcare from 2005 until 2010. Prior to joining Baxter, he worked for General Electric Healthcare, where he spent much of his 15 years in a variety of management roles for domestic and global businesses, culminating in leading the global functional imaging business. Mr. Arduini also serves on the Board of Directors of ADVAMED, the Board of Directors of MDIC, and the Board of Directors of the National Italian American Foundation. He also serves on the Board of Trustees of Susquehanna University. since 2016.
| Age | 56 |
| Tenure | 9 years |
| Address | Route 206 & Province Line Road, Princeton, NJ, United States, 08543 |
| Phone | 609 252 4621 |
| Web | https://www.bms.com |
Peter Arduini Latest Insider Activity
Tracking and analyzing the buying and selling activities of Peter Arduini against Bristol Myers stock is an integral part of due diligence when investing in Bristol Myers. Peter Arduini insider activity provides valuable insight into whether Bristol Myers is net buyers or sellers over its current business cycle. Note, Bristol Myers insiders must abide by specific rules, including filing SEC forms every time they buy or sell Bristol Myers'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Peter Arduini over six months ago Acquisition by Peter Arduini of 825 shares of Bristol Myers subject to Rule 16b-3 |
Bristol Myers Management Efficiency
The company has Return on Asset of 0.0655 % which means that on every $100 spent on assets, it made $0.0655 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.3895) %, meaning that it generated no profit with money invested by stockholders. Bristol Myers' management efficiency ratios could be used to measure how well Bristol Myers manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to -0.18 in 2025. Return On Capital Employed is likely to drop to 0.08 in 2025. At this time, Bristol Myers' Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 66 B in 2025, whereas Other Assets are likely to drop slightly above 3.3 B in 2025.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Karen Walker | Eli Lilly and | 59 | |
| Peter Wendell | Merck Company | 70 | |
| Edward Liddy | AbbVie Inc | 75 | |
| Leslie Brun | Merck Company | 68 | |
| Anne Mulcahy | Johnson Johnson | 68 | |
| Scott Gottlieb | Pfizer Inc | 48 | |
| Mary Coe | Merck Company | 54 | |
| Helen Hobbs | Pfizer Inc | 68 | |
| Marillyn Hewson | Johnson Johnson | 67 | |
| Brett Hart | AbbVie Inc | 51 | |
| Shantanu Narayen | Pfizer Inc | 57 | |
| Wyllie Cornwell | Pfizer Inc | 71 | |
| James Kilts | Pfizer Inc | 71 | |
| Carolyn Bertozzi | Eli Lilly and | 53 | |
| Gabrielle Sulzberger | Eli Lilly and | 60 | |
| Raul Alvarez | Eli Lilly and | 65 | |
| Kathi Seifert | Eli Lilly and | 70 | |
| Juan Luciano | Eli Lilly and | 59 | |
| Darius Adamczyk | Johnson Johnson | 55 | |
| William Kaelin | Eli Lilly and | 63 | |
| Mary Beckerle | Johnson Johnson | 66 | |
Management Performance
| Return On Equity | -0.39 | ||||
| Return On Asset | 0.0655 |
Bristol Myers Squibb Leadership Team
Elected by the shareholders, the Bristol Myers' board of directors comprises two types of representatives: Bristol Myers inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Bristol. The board's role is to monitor Bristol Myers' management team and ensure that shareholders' interests are well served. Bristol Myers' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Bristol Myers' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jitendra Tyagi, Head India | ||
| Adam Dubow, Senior Vice President, Chief Compliance Officer and Ethics Officer, Member of the Leadership Team | ||
| Michael Bonney, Independent Director | ||
| Robert Bertolini, Independent Director | ||
| Catherine Owen, Senior Markets | ||
| Lynelle Hoch, President Organization | ||
| Phyllis Yale, Independent Director | ||
| John Elicker, Senior Vice President - Corporate Affairs and Investor Relations | ||
| BCH BM, Ex Devel | ||
| Karen Santiago, Senior Vice President, Corporate Controller | ||
| Rupert Vessey, Executive Vice President - Research and Early Development, Member of the Leadership Team | ||
| Giovanni Caforio, Chairman of the Board, Chief Executive Officer | ||
| Nadim Ahmed, Executive Vice President and President - Hematology | ||
| Cari Gallman, Executive Affairs | ||
| Karin Shanahan, Executive Supply | ||
| Matthew Emmens, Independent Director | ||
| Ann Judge, Chief Human Resource Officer, Senior Vice President Member of the Leadership Team | ||
| Wendy Bartie, Senior Hematology | ||
| Sandra Leung, Executive Vice President, General Counsel, Member of the Leadership Team | ||
| Ahn Poole, Executive Officer | ||
| Paul Autenried, Executive Vice President, Chief Information Officer, Member of the Leadership Team | ||
| Samit Hirawat, Executive Vice President, Chief Medical Officer, Global Drug Development, Member of the Leadership Team | ||
| Tim Power, Vice President of Investor Relations | ||
| Giovanni MD, Executive Board | ||
| Greg Meyers, Executive Vice President Chief Digital and Technology Officer, Member of the Leadership Team | ||
| Kathryn Metcalfe, Executive Vice President - Corporate Affairs Member of the Leadership Team | ||
| Peter Arduini, Independent Director | ||
| Michelle Weese, Executive Vice President - Corporate Affairs, Member of the Leadership Team | ||
| Joseph Eiden, Head Affairs | ||
| Elizabeth Mily, Executive Vice President - Strategy and Business Development, Member of the Leadership Team | ||
| Ann Powell, Chief Human Resource Officer, Senior Vice President, Member of the Leadership Team | ||
| Karen Vousden, Independent Director | ||
| Paula Price, Independent Director | ||
| Gerald Storch, Independent Director | ||
| Sandra Esq, Executive Counsel | ||
| Louis Schmukler, Executive Vice President, President - Global Product Development and Supply, Member of the Leadership Team | ||
| Peter III, Senior CEO | ||
| Christopher Boerner, Executive Vice President and Chief Commercial Officer, Member of the Leadership Team | ||
| Catherine Adams, Senior Markets | ||
| Kimberly Jablonski, Chief Officer | ||
| David Elkins, Executive Vice President and Chief Financial Officer Member of the Leadership Team | ||
| Vicki Sato, Lead Independent Director | ||
| Manuel Medina, Independent Director | ||
| Julia Haller, Independent Director | ||
| Fernando Salinas, Chief Commercialization | ||
| Joseph Eid, Senior Vice President and Head of Global Medical Affairs, Member of the Leadership Team | ||
| Derica Rice, Independent Director | ||
| Dinesh Paliwal, Independent Director | ||
| Theodore Samuels, Lead Independent Director | ||
| Timothy Power, VP Relations | ||
| Adam Lenkowsky, Executive Officer | ||
| Samit MD, Executive Development |
Bristol Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Bristol Myers a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.39 | ||||
| Return On Asset | 0.0655 | ||||
| Profit Margin | (0.19) % | ||||
| Operating Margin | 0.23 % | ||||
| Current Valuation | 148.33 B | ||||
| Shares Outstanding | 2.03 B | ||||
| Shares Owned By Insiders | 0.07 % | ||||
| Shares Owned By Institutions | 80.57 % | ||||
| Number Of Shares Shorted | 37.01 M | ||||
| Price To Earning | 24.88 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Additional Tools for Bristol Stock Analysis
When running Bristol Myers' price analysis, check to measure Bristol Myers' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bristol Myers is operating at the current time. Most of Bristol Myers' value examination focuses on studying past and present price action to predict the probability of Bristol Myers' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bristol Myers' price. Additionally, you may evaluate how the addition of Bristol Myers to your portfolios can decrease your overall portfolio volatility.